Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009

Emerging Infectious Diseases

Volumn 17, Issue 10, 2011, Pages 1846-1854

  van der Linden, Jan W M ^a   Snelders, Eveline ^a   Kampinga, Greetje A ^b   Rijnders, Bart J A ^c   Mattsson, Eva ^d   Debets Ossenkopp, Yvette J ^e   Kuijper, Ed J ^f   van Tiel, Frank H ^g   Melchers, Willem J G ^a   Verweij, Paul E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; POLYENE; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CENTRAL NERVOUS SYSTEM ASPERGILLOSIS; CHILD; CONTROLLED STUDY; DISEASE SURVEILLANCE; DRUG EXPOSURE; FATALITY; FEMALE; FUNGUS ISOLATION; HEMATOLOGIC DISEASE; HUMAN; INFANT; INVASIVE ASPERGILLOSIS; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NEOPLASM; NETHERLANDS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; PREVALENCE; PROSPECTIVE STUDY; SCHOOL CHILD;

EID: 84930481483     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1710.110226     Document Type: Article

References (37)

1. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327-60.doi:10.1086/525258
2. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-15. doi:10.1056/NEJMoa020191
3. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346:225-34. doi:10.1056/ NEJM200201243460403
4. Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Cornely OA, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood. 2005;106:2641-5.doi:10.1182/ blood-2005-02-0733
5. Slobbe L, Polinder S, Doorduijn JK, Lugtenburg PJ, el Barzouhi A, Steyerberg EW, et al. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin Infect Dis. 2008;47:1507-12.doi:10.1086/591531
6. Snelders E, van der Lee HAL, Kuijpers J, Rijs AJMM, Varga J, Samson RA, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 2008;5:e219. doi:10.1371/journal.pmed.0050219
7. Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto AC, et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis. 2009;15:1068-76.doi:10.3201/eid1507.090043
8. Bueid A, Howard SJ, Moore CB, Richardson MD, Harrison E, Bowyer P, et al. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother. 2010;65:2116-8.doi:10.1093/jac/dkq279
9. Warris A, Weemaes CM, Verweij PE. Multidrug resistance in Aspergillus fumigatus. N Engl J Med. 2002;347:2173-4.doi:10.1056/ NEJM200212263472618
10. Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med. 2007;356:1481-3.doi:10.1056/ NEJMc061720
11. Mellado E, Garcia-Effron G, Alcázar-Fuoli L, Melchers WJ, Verweij PE, Cuenca-Estrella M, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother. 2007;51:1897-904.doi:10.1128/AAC.01092-06
12. Lagrou K, De Vleeschouwer J, Meerseman W, Dupont L, Verleden G, Melchers WJG, et al. Triazole resistance among 229 clinical Aspergillus fumigatus isolates. Presented at: 3rd Advances Against Aspergillosis Conference; Miami, Florida, USA; January 16-19, 2008. Abstract 33.
13. Arendrup MC, Perkhofer S, Howard SJ, Garcia-Effron G, Vishukumar A, Perlin D, et al. Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob Agents Chemother. 2008;52:3504-11.doi:10.1128/ AAC.00190-08
14. Chryssanthou E. In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B acquired resistance to itraconazole. Scand J Infect Dis. 1997;29:509-12.doi:10.3109/00365549709011864
15. Dannaoui E, Borel E, Monier MF, Piens MA, Picot S, Persat F. Acquired itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother. 2001;47:333-40.doi:10.1093/jac/47.3.333
16. Denning DW, Radford SA, Oakley KL, Hall L, Johnson EM, Warnock DW. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother. 1997;40:401-14.doi:10.1093/jac/40.3.401
17. Chen J, Li H, Li R, Bu D, Wan Z. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J Antimicrob Chemother. 2005;55:31-7 doi:10.1093/jac/dkh507
18. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL. Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother. 2004;48:2747-50.doi:10.1128/ AAC.48.7.2747-2750.2004
19. Diaz-Guerra TM, Mellado E, Cuenca-Estrella M, Rodriguez-Tudela JL. A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 2003;47:1120-4.doi:10.1128/ AAC.47.3.1120-1124.2003
20. Verweij PE, Howard SJ, Melchers WJG, Denning DW. Azole resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat. 2009;12:141-7.doi:10.1016/j.drup.2009.09.002
21. Snelders E. Karawajczyk, Schaftenaar G, Verweij PE, Melchers WJ. Azole resistance profile of amino acid changes in Aspergillus fumigatus cyp51A based on protein homology modeling. Antimicrob Agents Chemother. 2010;54:2425-30.doi:10.1128/AAC.01599-09
22. van Leer-Buter C, Takes RP, Hebeda KM, Melchers WJ, Verweij PE. Aspergillosis-and a misleading sensitivity result. Lancet. 2007;370:102.doi:10.1016/S0140-6736(07)61055-1
23. van der Linden JW, Jansen RR, Bresters D, Visser CE, Geerlings SE, Kuijper EJ, et al. Azole resistant central nervous system aspergillosis. Clin Infect Dis. 2009;48:1111-3.doi:10.1086/597465
24. Hodiamont CJ, Dolman KM, ten Berge RJM, Melchers WJ, Verweij PE, Pajkrt D. Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. Med Mycol. 2009;47:217-20.doi:10.1080/13693780802545600
25. Mavridou E, Brüggemann RJ, Melchers WJ, Verweij PE, Mouton JW. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother. 2010;54:4758-64.doi:10.1128/AAC.00606-10
26. Mavridou E, Brüggemann RJ, Melchers WJ, Mouton JW, Verweij PE. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother. 2010;54:860-5.doi:10.1128/AAC.00931-09
27. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis. 2009;9:789-95.doi:10.1016/ S1473-3099(09)70265-8
28. Snelders E, Huisin't Veld RAG, Rijs AJJM, Kema GHJ, Melchers WJ, Verweij PE. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol. 2009;75:4053-7.doi:10.1128/AEM.00231-09
29. Mortensen KL, Mellado E, Lass-Flörl C, Rodriguez-Tudela JL, Johansen HK, Arendrup MC. Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Antimicrob Agents Chemother. 2010;54:4545-9.doi:10.1128/AAC.00692-10
30. Verweij PE, Te Dorsthorst DT, Rijs AJ, De Vries-Hospers HG, Meis JF. Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998. J Clin Microbiol. 2002;40:2648-50.doi:10.1128/JCM.40.7.2648-2650.2002
31. Klaassen CH, de Valk HA, Curfs-Breuker IM, Meis JF. Novel mixed-format real-time PCR assay to detect mutations conferring resistance to triazoles in Aspergillus fumigatus and prevalence of multi-triazole resistance among clinical isolates in the Netherlands. J Antimicrob Chemother. 2010;65:901-5.doi:10.1093/jac/dkq041
32. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. CLSI document M38-A2. Wayne (PA): The Institute; 2008.
33. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the EORTC/MSG. Clin Infect Dis. 2008;46:1813-21.doi:10.1086/588660
34. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-74.doi:10.2307/2529310
35. Baddley JW, Marr KA, Andes DR, Walsh TJ, Kauffman CA, Kontoyiannis DP, et al. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol. 2009;47:3271-5.doi:10.1128/JCM.00854-09
36. van der Linden JW, Snelders E, Arends JP, Daenen SM, Melchers WJ, Verweij PE. Rapid diagnosis of azole-resistant aspergillosis by direct PCR using tissue specimens. J Clin Microbiol. 2010;48:1478-80.doi:10.1128/JCM.02221-09
37. Denning DW, Park S, Lass-Florl C, Fraczek MG, Kirwan M, Gore R, et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis. 2011;52:1123-9.doi:10.1093/cid/cir179